Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1997 2
1998 5
1999 5
2000 3
2001 1
2002 3
2003 1
2004 2
2005 3
2007 8
2008 12
2009 19
2010 19
2011 19
2012 16
2013 16
2014 6
2015 12
2016 6
2017 4
2018 10
2019 9
2020 4
2021 9
2022 5
2023 16
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Tostmann A, et al. Among authors: boeree mj. J Gastroenterol Hepatol. 2008 Feb;23(2):192-202. doi: 10.1111/j.1440-1746.2007.05207.x. Epub 2007 Nov 6. J Gastroenterol Hepatol. 2008. PMID: 17995946 Review.
Recent advances in the treatment of tuberculosis.
Motta I, Boeree M, Chesov D, Dheda K, Günther G, Horsburgh CR Jr, Kherabi Y, Lange C, Lienhardt C, McIlleron HM, Paton NI, Stagg HR, Thwaites G, Udwadia Z, Van Crevel R, Velásquez GE, Wilkinson RJ, Guglielmetti L; Study group on Mycobacteria (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Motta I, et al. Among authors: boeree m. Clin Microbiol Infect. 2023 Jul 22:S1198-743X(23)00339-7. doi: 10.1016/j.cmi.2023.07.013. Online ahead of print. Clin Microbiol Infect. 2023. PMID: 37482332 Review.
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, Grobusch MP, Gröschel MI, Guglielmetti L, Kontsevaya I, Lange B, van Leth F, Lienhardt C, Mandalakas AM, Maurer FP, Merker M, Miotto P, Molina-Moya B, Morel F, Niemann S, Veziris N, Whitelaw A, Horsburgh CR Jr, Lange C; TBnet and RESIST-TB networks. Domínguez J, et al. Among authors: boeree mj. Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28. Lancet Infect Dis. 2023. PMID: 36868253 Review.
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilb… See abstract for full author list ➔ Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, et al. Among authors: boeree mj. Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Lancet. 2018. PMID: 30215381 Free PMC article. Review.
XDR tuberculosis.
van Ingen J, de Lange WC, Boeree MJ, Iseman MD, Daley CL, Heifets LB, Böttger EC, van Soolingen D. van Ingen J, et al. Among authors: boeree mj. Lancet Infect Dis. 2011 Aug;11(8):585. doi: 10.1016/S1473-3099(11)70200-6. Lancet Infect Dis. 2011. PMID: 21798459 No abstract available.
[Nontuberculous mycobacteria: clinically relevant].
van Ingen J, Hoefsloot W, de Lange WC, Magis-Escurra C, Dekhuijzen PN, Boeree MJ, van Soolingen D. van Ingen J, et al. Among authors: boeree mj. Ned Tijdschr Geneeskd. 2010;154:A1178. Ned Tijdschr Geneeskd. 2010. PMID: 20482903 Review. Dutch.
Optimising pyrazinamide for the treatment of tuberculosis.
Zhang N, Savic RM, Boeree MJ, Peloquin CA, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PPJ, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE; Tuberculosis Trials Consortium (TBTC) and Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) Networks. Zhang N, et al. Among authors: boeree mj. Eur Respir J. 2021 Jul 20;58(1):2002013. doi: 10.1183/13993003.02013-2020. Print 2021 Jul. Eur Respir J. 2021. PMID: 33542052 Free PMC article. Clinical Trial.
199 results